Toggle navigation
Home
Pulse
Channels
CME
Profile
Home
Pulse
Channels
CME
Profile
tmodarressi's Talks
@tmodarressi
Advocare Princeton Cardiometabolic Health
Orforglipron (Foundayo) Cuts CV Risk & All-Cause Mortality
April 27, 2026
@tmodarressi
Advocare Princeton Cardiometabolic Health
Tirzepatide Beats Dulaglutide for Cardiorenal Endpoints
April 27, 2026
Share
Tirzepatide Beats Dulaglutide for Cardiorenal Endpoints
https://www.medspoke.co/channel_playlist?object_id=804&tap_id=11091
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
@tmodarressi
Advocare Princeton Cardiometabolic Health
Implantable & Ultra-Long-Acting GLP1RA
April 27, 2026
Why are you reporting this TALK?
